Liquidia Dividends and Buybacks
Dividend criteria checks 0/6
Liquidia does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.1%
Buyback Yield
| Total Shareholder Yield | -0.1% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow
Summary YUTREPIA's commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially. Q2 largely resolved the margin concern: product gross margin remained about 93.7% despite fully costed inventory, while operating margin reached roughly 49.8%. The key debate has shifted from profitability to growth. Liquidia now needs about $210 million of quarterly revenue in Q3 and Q4 to reach the current $725 million FY2026 consensus. Read the full article on Seeking Alpha
LQDA: Future Patent Decisions Seen Driving Upside As Sentiment Turns More Positive
Analysts have lifted their fair value estimate for Liquidia stock from $102.99 to $130.00, reflecting updated assumptions on litigation outcomes around YUTREPIA and views that the drug could play a central role in treating PAH and PH-ILD if current legal and intellectual property questions are resolved in the company's favor. Analyst Commentary Recent Street research on Liquidia highlights a mix of optimism and caution that centers on litigation milestones, the commercial trajectory of YUTREPIA, and how these factors could influence the stock's valuation over time.
LQDA: Pending Patent Outcomes Will Drive Future Earnings Upside Or Downside
Analysts lifted their fair value estimate for Liquidia to $60.00 from $16.99, citing higher Street price targets, stronger conviction in Yutrepia's potential positioning in PAH and PH-ILD, and updated assumptions around earnings power and legal outcomes. These changes are reflected in revised discount rate, margin, and future P/E inputs.LQDA: Legal Outcomes Around Key Patent Will Drive Future Upside
Analysts have lifted their implied fair value estimate for Liquidia from about $67.00 to roughly $103.00, citing updated models that reflect stronger expectations for Yutrepia, higher peak sales assumptions up to $2.2b, and legal outcomes that they view as better framed after recent court decisions. Some now prefer to wait for more clarity on key patent litigation before assuming further upside.
LQDA: Legal Outcomes And Earnings Power Will Shape The Next Phase
Analysts have lifted the updated fair value estimate for Liquidia to $72.38 from $44.00, as higher assumed profit margins, a lower future P/E multiple, and evolving views on legal and earnings risk reshape their price target frameworks. Analyst Commentary Recent Street research on Liquidia highlights a mix of enthusiasm around potential earnings power and caution around legal outcomes, which together shape how analysts think about valuation and execution risk.Liquidia (LQDA) Stock Could Be 63.2% Overvalued After PHA 2026 YUTREPIA Update
Liquidia (LQDA) is back in focus after the company outlined four new poster presentations at the PHA 2026 International PH Conference, spotlighting fresh YUTREPIA data and broader pulmonary hypertension care insights. See our latest analysis for Liquidia. The PHA 2026 conference update comes at a time when Liquidia’s momentum has been strong, with a 30 day share price return of 26.12% and a 5 year total shareholder return of 2,737.94%. Together, these figures point to sentiment that has...Upgrade: Analysts Just Made A Captivating Increase To Their Liquidia Corporation (NASDAQ:LQDA) Forecasts
Shareholders in Liquidia Corporation ( NASDAQ:LQDA ) may be thrilled to learn that the analysts have just delivered a...Liquidia Corporation (NASDAQ:LQDA) Looks Just Right With A 30% Price Jump
Liquidia Corporation ( NASDAQ:LQDA ) shares have had a really impressive month, gaining 30% after a shaky period...Liquidia Corporation's Long-Running Saga Is Coming To An End
Summary Today, we are circling back on Liquidia Corporation, as its long-running litigation battle with United Therapeutics is finally coming to a positive end. This means we will likely see the full commercial launch of its primary candidate, YUTREPIA before the end of the second market. YUTREPIA is targeting a large potential market and could garner significant market share. An updated analysis around Liquidia Corporation follows in the paragraphs below. Read the full article on Seeking AlphaStability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if LQDA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LQDA's dividend payments have been increasing.
Dividend Yield vs Market
| Liquidia Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (LQDA) | n/a |
| Market Bottom 25% (US) | 1.3% |
| Market Top 25% (US) | 4.0% |
| Industry Average (Pharmaceuticals) | 1.8% |
| Analyst forecast (LQDA) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate LQDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LQDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate LQDA's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LQDA has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/19 04:17 |
| End of Day Share Price | 2026/08/19 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Liquidia Corporation is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Julian Harrison | BTIG |
| Andrew Fein | H.C. Wainwright & Co. |